Richard Greil

800 total citations
10 papers, 58 citations indexed

About

Richard Greil is a scholar working on Neurology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Richard Greil has authored 10 papers receiving a total of 58 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Neurology, 4 papers in Pathology and Forensic Medicine and 3 papers in Genetics. Recurrent topics in Richard Greil's work include CNS Lymphoma Diagnosis and Treatment (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Glioma Diagnosis and Treatment (2 papers). Richard Greil is often cited by papers focused on CNS Lymphoma Diagnosis and Treatment (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Glioma Diagnosis and Treatment (2 papers). Richard Greil collaborates with scholars based in Austria, Spain and Germany. Richard Greil's co-authors include Jens Krugmann, Michael Fiegl, S Dirnhofer, Michael Straßer, Ninon Taylor, Elisabeth Haschke‐Becher, Stefan Dirnhofer, Alexander von Smekal, Bettina Pfausler and Armin Muigg and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and British Journal of Haematology.

In The Last Decade

Richard Greil

10 papers receiving 57 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Greil Austria 6 36 27 21 11 9 10 58
Teresa M. Cardesa‐Salzmann Germany 4 27 0.8× 16 0.6× 12 0.6× 9 0.8× 6 57
Sara Pezzatti Italy 4 10 0.3× 28 1.0× 6 0.3× 41 3.7× 3 0.3× 10 64
V. Di Tommaso Italy 5 16 0.4× 48 1.8× 2 0.1× 9 0.8× 4 0.4× 8 73
Selim Jennane Morocco 5 5 0.1× 15 0.6× 10 0.5× 10 0.9× 1 0.1× 16 40
Riccardo Bruna Italy 4 21 0.6× 59 2.2× 16 0.8× 35 3.2× 2 0.2× 13 90
László Imre Pinczés Hungary 5 27 0.8× 32 1.2× 13 0.6× 26 2.4× 1 0.1× 23 70
Soumaya El Mahou France 4 13 0.4× 8 0.3× 10 0.5× 4 0.4× 8 61
Amaury Leruste France 6 18 0.5× 32 1.2× 5 0.2× 37 3.4× 12 84
Marie‐Pierre Moles‐Moreau France 4 35 1.0× 56 2.1× 47 2.2× 5 0.5× 1 0.1× 9 66
Marek Śmiłowski Poland 4 25 0.7× 8 0.3× 3 0.1× 4 0.4× 10 39

Countries citing papers authored by Richard Greil

Since Specialization
Citations

This map shows the geographic impact of Richard Greil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Greil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Greil more than expected).

Fields of papers citing papers by Richard Greil

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Greil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Greil. The network helps show where Richard Greil may publish in the future.

Co-authorship network of co-authors of Richard Greil

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Greil. A scholar is included among the top collaborators of Richard Greil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Greil. Richard Greil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
Cutsem, Eric Van, Rikke Løvendahl Eefsen, Sebastian Ochsenreither, et al.. (2022). Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).. Journal of Clinical Oncology. 40(16_suppl). 4141–4141. 5 indexed citations
3.
Bernard, Sophie, Hervé Ghesquières, Olivier Casasnovas, et al.. (2021). Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. Blood Advances. 5(15). 2965–2968. 7 indexed citations
4.
Awada, Ahmad, Sebastian Ochsenreither, Rikke Løvendahl Eefsen, et al.. (2021). Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.. Journal of Clinical Oncology. 39(15_suppl). e16228–e16228. 2 indexed citations
5.
6.
Taylor, Ninon, Klaudija Bijuklic, Alexander Egle, et al.. (2008). Elite controllers or misquantification of virus load by Cobas TaqMan?. Journal of the International AIDS Society. 11(Suppl 1). P200–P200. 1 indexed citations
7.
Fiegl, Michael, Armin Muigg, Alexander von Smekal, et al.. (2002). Diffuse Large B-cell Lymphoma with Infiltration-Associated Peripheral Neuropathy and Paraneoplastic Myopathy with a Prolonged Course Over Seven Years. Leukemia & lymphoma. 43(8). 1687–1690. 5 indexed citations
8.
Fiegl, Michael, et al.. (2002). Intravascular large B-cell lymphoma with a fulminant clinical course: a case report with definite diagnosis post mortem. Annals of Oncology. 13(9). 1503–1506. 22 indexed citations
9.
Pfausler, Bettina, et al.. (1995). Multimodal Therapy in Life-Threatening Cerebral Lupus erythematosus: The Benefit of Cerebrospinal Fluid Pheresis. International Archives of Allergy and Immunology. 107(4). 592–594. 5 indexed citations
10.
Ransmayr, Gerhard, K Twerdy, H. Zwierzina, et al.. (1993). EXTENSIVE MENINGEAL INVOLVEMENT AS THE PRIMARY MANIFESTATION OF A SYSTEMIC SMALL LYMPHOCYTIC LYMPHOMA: FAVOURABLE OUTCOME AFTER NEURAXIAL IRRADIATION WITHOUT CHEMOTHERAPY. British Journal of Haematology. 83(4). 674–675. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teresa M. Cardesa‐Salzmann Breakdown of academic impact, for papers by Sara Pezzatti Breakdown of academic impact, for papers by V. Di Tommaso Breakdown of academic impact, for papers by Selim Jennane Breakdown of academic impact, for papers by Riccardo Bruna Breakdown of academic impact, for papers by László Imre Pinczés Breakdown of academic impact, for papers by Soumaya El Mahou Breakdown of academic impact, for papers by Amaury Leruste Breakdown of academic impact, for papers by Marie‐Pierre Moles‐Moreau Breakdown of academic impact, for papers by Marek Śmiłowski
Rankless by CCL
2026